In:
PLOS Genetics, Public Library of Science (PLoS), Vol. 17, No. 2 ( 2021-2-18), p. e1009323-
Abstract:
Preemptive pharmacogenetic testing has the potential to improve drug dosing by providing point-of-care patient genotype information. Nonetheless, its implementation in the Chinese population is limited by the lack of population-wide data. In this study, secondary analysis of exome sequencing data was conducted to study pharmacogenomics in 1116 Hong Kong Chinese. We aimed to identify the spectrum of actionable pharmacogenetic variants and rare, predicted deleterious variants that are potentially actionable in Hong Kong Chinese, and to estimate the proportion of dispensed drugs that may potentially benefit from genotype-guided prescription. The projected preemptive pharmacogenetic testing prescription impact was evaluated based on the patient prescription data of the public healthcare system in 2019, serving 7.5 million people. Twenty-nine actionable pharmacogenetic variants/ alleles were identified in our cohort. Nearly all (99.6%) subjects carried at least one actionable pharmacogenetic variant, whereas 93.5% of subjects harbored at least one rare deleterious pharmacogenetic variant. Based on the prescription data in 2019, 13.4% of the Hong Kong population was prescribed with drugs with pharmacogenetic clinical practice guideline recommendations. The total expenditure on actionable drugs was 33,520,000 USD, and it was estimated that 8,219,000 USD (24.5%) worth of drugs were prescribed to patients with an implicated actionable phenotype. Secondary use of exome sequencing data for pharmacogenetic analysis is feasible, and preemptive pharmacogenetic testing has the potential to support prescription decisions in the Hong Kong Chinese population.
Type of Medium:
Online Resource
ISSN:
1553-7404
DOI:
10.1371/journal.pgen.1009323
DOI:
10.1371/journal.pgen.1009323.g001
DOI:
10.1371/journal.pgen.1009323.g002
DOI:
10.1371/journal.pgen.1009323.g003
DOI:
10.1371/journal.pgen.1009323.g004
DOI:
10.1371/journal.pgen.1009323.t001
DOI:
10.1371/journal.pgen.1009323.s001
DOI:
10.1371/journal.pgen.1009323.s002
DOI:
10.1371/journal.pgen.1009323.s003
DOI:
10.1371/journal.pgen.1009323.s004
DOI:
10.1371/journal.pgen.1009323.s005
DOI:
10.1371/journal.pgen.1009323.s006
DOI:
10.1371/journal.pgen.1009323.s007
DOI:
10.1371/journal.pgen.1009323.s008
DOI:
10.1371/journal.pgen.1009323.s009
DOI:
10.1371/journal.pgen.1009323.s010
DOI:
10.1371/journal.pgen.1009323.s011
DOI:
10.1371/journal.pgen.1009323.s012
DOI:
10.1371/journal.pgen.1009323.s013
DOI:
10.1371/journal.pgen.1009323.s014
DOI:
10.1371/journal.pgen.1009323.s015
DOI:
10.1371/journal.pgen.1009323.s016
DOI:
10.1371/journal.pgen.1009323.s017
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2186725-2
Bookmarklink